120 related articles for article (PubMed ID: 34896436)
1. p21 activated kinase-1 and tamoxifen - A deadly nexus impacting breast cancer outcomes.
Rajendran S; Swaroop SS; Roy J; Inemai E; Murugan S; Rayala SK; Venkatraman G
Biochim Biophys Acta Rev Cancer; 2022 Jan; 1877(1):188668. PubMed ID: 34896436
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer.
Bostner J; Skoog L; Fornander T; Nordenskjöld B; Stål O
Clin Cancer Res; 2010 Mar; 16(5):1624-33. PubMed ID: 20179234
[TBL] [Abstract][Full Text] [Related]
3. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.
Bostner J; Ahnström Waltersson M; Fornander T; Skoog L; Nordenskjöld B; Stål O
Oncogene; 2007 Oct; 26(49):6997-7005. PubMed ID: 17486065
[TBL] [Abstract][Full Text] [Related]
4. PKA-induced phosphorylation of ERα at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer.
Kok M; Zwart W; Holm C; Fles R; Hauptmann M; Van't Veer LJ; Wessels LF; Neefjes J; Stål O; Linn SC; Landberg G; Michalides R
Breast Cancer Res Treat; 2011 Jan; 125(1):1-12. PubMed ID: 20213082
[TBL] [Abstract][Full Text] [Related]
5. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
Holm C; Rayala S; Jirström K; Stål O; Kumar R; Landberg G
J Natl Cancer Inst; 2006 May; 98(10):671-80. PubMed ID: 16705121
[TBL] [Abstract][Full Text] [Related]
6. Sliding p21-activated kinase 1 to nucleus impacts tamoxifen sensitivity.
Rayala SK; Kumar R
Biomed Pharmacother; 2007 Aug; 61(7):408-11. PubMed ID: 17604944
[TBL] [Abstract][Full Text] [Related]
7. Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer.
Lundgren K; Holm K; Nordenskjöld B; Borg A; Landberg G
Breast Cancer Res; 2008; 10(5):R81. PubMed ID: 18823530
[TBL] [Abstract][Full Text] [Related]
8. The investigation of miR-221-3p and PAK1 gene expressions in breast cancer cell lines.
Ergun S; Tayeb TS; Arslan A; Temiz E; Arman K; Safdar M; Dağlı H; Korkmaz M; Nacarkahya G; Kırkbeş S; Oztuzcu S
Gene; 2015 Jan; 555(2):377-81. PubMed ID: 25447917
[TBL] [Abstract][Full Text] [Related]
9. Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study.
Ahern TP; Cronin-Fenton DP; Lash TL; Sørensen HT; Ording AG; Hamilton-Dutoit SJ; Hellberg Y
Acta Oncol; 2016 Jun; 55(6):734-41. PubMed ID: 27056567
[TBL] [Abstract][Full Text] [Related]
10. [The role of protein kinase PAK1 in the regulation of estrogen-independent growth of breast cancer].
Avilova EA; Andreeva OE; Shatskaia VA; Krasil'nikov MA
Biomed Khim; 2014; 60(3):322-31. PubMed ID: 25019394
[TBL] [Abstract][Full Text] [Related]
11. Regulation of tamoxifen sensitivity by a PAK1-EBP1 signalling pathway in breast cancer.
Ghosh A; Awasthi S; Peterson JR; Hamburger AW
Br J Cancer; 2013 Feb; 108(3):557-63. PubMed ID: 23361053
[TBL] [Abstract][Full Text] [Related]
12. Current trends and opportunities in targeting p21 activated kinase-1(PAK1) for therapeutic management of breast cancers.
Kanumuri R; Saravanan R; Pavithra V; Sundaram S; Rayala SK; Venkatraman G
Gene; 2020 Nov; 760():144991. PubMed ID: 32717309
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological inhibition of Rac1-PAK1 axis restores tamoxifen sensitivity in human resistant breast cancer cells.
Gonzalez N; Cardama GA; Comin MJ; Segatori VI; Pifano M; Alonso DF; Gomez DE; Menna PL
Cell Signal; 2017 Jan; 30():154-161. PubMed ID: 27939839
[TBL] [Abstract][Full Text] [Related]
14. Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance.
Hirokawa Y; Arnold M; Nakajima H; Zalcberg J; Maruta H
Cancer Biol Ther; 2005 Sep; 4(9):956-60. PubMed ID: 16082189
[TBL] [Abstract][Full Text] [Related]
15. Nuclear p21-activated kinase 1 in breast cancer packs off tamoxifen sensitivity.
Rayala SK; Molli PR; Kumar R
Cancer Res; 2006 Jun; 66(12):5985-8. PubMed ID: 16778166
[TBL] [Abstract][Full Text] [Related]
16. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
[No Abstract] [Full Text] [Related]
17. p21-activated kinase group II small compound inhibitor GNE-2861 perturbs estrogen receptor alpha signaling and restores tamoxifen-sensitivity in breast cancer cells.
Zhuang T; Zhu J; Li Z; Lorent J; Zhao C; Dahlman-Wright K; Strömblad S
Oncotarget; 2015 Dec; 6(41):43853-68. PubMed ID: 26554417
[TBL] [Abstract][Full Text] [Related]
18. P21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation.
Rayala SK; Talukder AH; Balasenthil S; Tharakan R; Barnes CJ; Wang RA; Aldaz CM; Khan S; Kumar R
Cancer Res; 2006 Feb; 66(3):1694-701. PubMed ID: 16452229
[TBL] [Abstract][Full Text] [Related]
19. Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition.
Villamar Cruz O; Prudnikova TY; Araiza-Olivera D; Perez-Plasencia C; Johnson N; Bernhardy AJ; Slifker M; Renner C; Chernoff J; Arias-Romero LE
Oncotarget; 2016 Nov; 7(47):76590-76603. PubMed ID: 27740936
[TBL] [Abstract][Full Text] [Related]
20. IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer.
Zhang Y; Wester L; He J; Geiger T; Moerkens M; Siddappa R; Helmijr JA; Timmermans MM; Look MP; van Deurzen CHM; Martens JWM; Pont C; de Graauw M; Danen EHJ; Berns EMJJ; Meerman JHN; Jansen MPHM; van de Water B
Oncogene; 2018 Apr; 37(14):1869-1884. PubMed ID: 29353882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
